🇺🇸 FDA
Patent

US 10088485

Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand

granted A61KA61K31/00A61K31/427

Quick answer

US patent 10088485 (Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand) held by Regen Biopharma, Inc. expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regen Biopharma, Inc.
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/00, A61K31/427, A61K31/7088